Calliditas Therapeutics AB financials
Calliditas Therapeutics AB
Country: SE Reporting currency: SEK Latest annual report: 2023-12-31
LEI:
549300PVPZO8TNT76B58 Financial statements
(SEK, as reported — unscaled; 102 line items across 3 annual periods)
| Line item | 2023 | 2022 | 2021 |
|---|---|---|---|
| Income statement | |||
| Cost of sales | SEK 60.5M | SEK 15.2M | SEK 0 |
| Gross profit | SEK 1.15B | SEK 787.7M | SEK 229.3M |
| Other income | SEK 44.6M | SEK 2.9M | SEK 259.0K |
| Administrative expenses | SEK 333.0M | SEK 259.5M | SEK 210.6M |
| Operating profit (EBIT) | -SEK 373.1M | -SEK 421.9M | -SEK 524.5M |
| Finance costs | SEK 114.3M | SEK 37.7M | SEK 9.3M |
| Profit before tax | -SEK 457.0M | -SEK 409.4M | -SEK 513.4M |
| Income tax expense | SEK 9.2M | SEK 2.9M | -SEK 3.8M |
| Profit for the year | -SEK 466.2M | -SEK 412.3M | -SEK 509.5M |
| — attributable to owners | -SEK 466.2M | -SEK 412.3M | -SEK 500.3M |
| — attributable to NCI | SEK 0 | SEK 0 | -SEK 9.2M |
| Total comprehensive income | -SEK 483.8M | -SEK 373.2M | -SEK 527.7M |
| Per share | |||
| Basic EPS | SEK -8.69 | SEK -7.78 | SEK -9.84 |
| Diluted EPS | SEK -8.69 | SEK -7.78 | SEK -9.84 |
| Free cash flow / share | SEK -8.34 | SEK -5.92 | SEK -9.04 |
| Cash flow statement | |||
| Net cash from operating activities | -SEK 434.7M | -SEK 311.4M | -SEK 461.6M |
| Net cash from investing activities | -SEK 13.7M | -SEK 5.1M | -SEK 24.3M |
| Purchase of PP&E (capex) | SEK 12.8M | SEK 2.5M | SEK 6.6M |
| Purchase of intangibles | SEK 0 | SEK 0 | SEK 16.1M |
| Net cash from financing activities | SEK 199.7M | SEK 576.0M | SEK 435.2M |
| Repayments of borrowings | SEK 724.5M | SEK 0 | SEK 0 |
| Lease liability payments | SEK 12.1M | SEK 9.6M | SEK 5.6M |
| Net change in cash | -SEK 248.8M | SEK 259.5M | -SEK 50.8M |
| Balance sheet | |||
| Total assets | SEK 1.86B | SEK 1.95B | — |
| Non-current assets | SEK 584.1M | SEK 540.8M | — |
| Property, plant & equipment | SEK 16.1M | SEK 7.5M | — |
| Intangible assets & goodwill | SEK 48.6M | SEK 45.8M | — |
| Current assets | SEK 1.28B | SEK 1.41B | — |
| Inventories | SEK 20.4M | SEK 3.6M | — |
| Trade & other receivables | SEK 180.9M | SEK 78.7M | — |
| Cash & equivalents | SEK 973.7M | SEK 1.25B | SEK 955.5M |
| Total equity | SEK 334.8M | SEK 766.3M | SEK 1.01B |
| — attributable to owners | SEK 334.8M | SEK 766.3M | — |
| Non-current liabilities | SEK 1.12B | SEK 861.5M | — |
| Long-term borrowings | SEK 939.5M | SEK 713.0M | — |
| Lease liabilities (non-current) | SEK 27.1M | SEK 15.8M | — |
| Current liabilities | SEK 407.1M | SEK 325.2M | — |
| Trade & other payables | SEK 100.6M | SEK 160.4M | — |
| Deferred tax liabilities | SEK 41.6M | SEK 39.8M | — |
| Derived metrics | |||
| Free cash flow | -SEK 447.4M | -SEK 313.9M | -SEK 468.2M |
| Operating margin | -30.9% | -52.6% | -228.7% |
| Net margin | -38.6% | -51.3% | -222.2% |
| Return on equity | -139.2% | -53.8% | -50.5% |
| Cash conversion ratio | 0.93× | 0.76× | 0.91× |
| Capex coverage | -33.99× | -123.95× | -70.06× |
| Other reported items | |||
| Accruals Classified As Current | SEK 280.6M | SEK 136.4M | — |
| Additional Paidin Capital | SEK 2.64B | SEK 2.59B | — |
| Adjustments For Decrease Increase In Inventories | -SEK 16.8M | -SEK 2.8M | -SEK 949.0K |
| Adjustments For Decrease Increase In Trade Account Receivable | -SEK 182.6M | -SEK 91.9M | -SEK 11.7M |
| Adjustments For Increase Decrease In Trade and Other Payables | SEK 119.6M | SEK 183.1M | SEK 18.1M |
| Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital | SEK 102.5M | SEK 61.3M | SEK 66.7M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 354.9M | -SEK 399.8M | -SEK 467.1M |
| Comprehensive Income Attributable To Noncontrolling Interests | SEK 0 | SEK 0 | -SEK 8.5M |
| Comprehensive Income Attributable To Owners of Parent | -SEK 483.8M | -SEK 373.2M | -SEK 519.2M |
| Current Prepayments and Current Accrued Income Other Than Current Contract Assets | SEK 84.3M | SEK 70.7M | — |
| Current Tax Liabilities Current | SEK 6.2M | SEK 5.7M | — |
| Deferred Tax Assets | SEK 26.3M | SEK 13.8M | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -SEK 26.6M | SEK 34.1M | SEK 10.0M |
| Equity and Liabilities | SEK 1.86B | SEK 1.95B | — |
| Finance Income | SEK 30.4M | SEK 50.2M | SEK 20.3M |
| Income Taxes Paid Refund Classified As Operating Activities | SEK 22.7M | SEK 7.4M | SEK 3.9M |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | — | — | -SEK 49.3M |
| Increase Decrease Through Exercise of Warrants Equity | — | SEK 95.1M | — |
| Increase Decrease Through Other Contributions By Owners | — | — | SEK 2.3M |
| Increase Decrease Through Sharebased Payment Transactions | SEK 52.3M | SEK 36.1M | SEK 23.6M |
| Increase Decrease Through Transactions With Owners | SEK 52.3M | SEK 131.2M | SEK 279.6M |
| Intangible Assets Other Than Goodwill | SEK 430.8M | SEK 438.1M | — |
| Interest Paid Classified As Operating Activities | SEK 94.5M | SEK 35.3M | SEK 5.4M |
| Interest Received Classified As Operating Activities | SEK 32.9M | SEK 3.6M | SEK 102.0K |
| Issue of Equity | — | — | SEK 324.0M |
| Issued Capital | SEK 2.4M | SEK 2.4M | — |
| Noncurrent Financial Assets | SEK 24.2M | SEK 11.2M | — |
| Noncurrent Recognised Liabilities Defined Benefit Plan | SEK 3.5M | SEK 884.0K | — |
| Other Comprehensive Income | -SEK 17.6M | SEK 39.0M | -SEK 18.1M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -SEK 14.5M | SEK 36.3M | -SEK 20.1M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -SEK 3.1M | SEK 2.8M | SEK 2.0M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -SEK 14.5M | SEK 36.3M | -SEK 20.1M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -SEK 3.1M | SEK 2.8M | SEK 2.0M |
| Other Current Assets | SEK 15.8M | SEK 10.0M | — |
| Other Current Liabilities | SEK 19.8M | SEK 22.7M | — |
| Other Expense By Function | SEK 1.1M | SEK 23.1M | SEK 6.3M |
| Other Longterm Provisions | SEK 32.6M | SEK 11.8M | — |
| Other Noncurrent Liabilities | SEK 16.4M | SEK 4.3M | — |
| Other Reserves | -SEK 5.2M | SEK 9.3M | — |
| Payments For Share Issue Costs | SEK 0 | SEK 0 | SEK 20.9M |
| Payments From Changes In Ownership Interests In Subsidiaries | SEK 0 | SEK 0 | SEK 49.3M |
| Payments To Acquire Or Redeem Entitys Shares | SEK 0 | SEK 236.0K | SEK 0 |
| Proceeds From Contributions of Noncontrolling Interests | SEK 0 | SEK 0 | SEK 2.3M |
| Proceeds From Exercise of Warrants | SEK 0 | SEK 95.1M | SEK 0 |
| Proceeds From Issuing Shares | SEK 0 | SEK 0 | SEK 324.0M |
| Proceeds From Noncurrent Borrowings | SEK 962.9M | SEK 491.7M | SEK 199.5M |
| Proceeds From Sale Or Issue of Treasury Shares | SEK 0 | SEK 236.0K | SEK 0 |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | SEK 602.0K | SEK 0 | SEK 0 |
| Purchase of Financial Instruments Classified As Investing Activities | SEK 1.6M | SEK 2.6M | SEK 1.7M |
| Purchase of Treasury Shares | — | SEK 236.0K | — |
| Research and Development Expense | SEK 502.2M | SEK 414.7M | SEK 357.5M |
| Retained Earnings | -SEK 2.31B | -SEK 1.84B | — |
| Revenue From Contracts With Customers | SEK 1.21B | SEK 802.9M | SEK 229.3M |
| Rightofuse Assets That Do Not Meet Definition of Investment Property | SEK 38.2M | SEK 24.5M | — |
| Sale Or Issue of Treasury Shares | — | SEK 236.0K | — |
| Sales and Marketing Expense | SEK 727.7M | SEK 515.2M | SEK 179.6M |
| Share Issue Related Cost | — | — | SEK 20.9M |
Methodology
Every line item above is a fact tagged in Calliditas Therapeutics AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.